Carvacrol enhances the sensitıvity of cetuximab in lung cancer cells through inducing apoptosis and cell cycle arrest
| dc.contributor.author | Erdogan, Ayse | |
| dc.contributor.author | Koras, Rahime Aybike | |
| dc.date.accessioned | 2026-01-24T12:29:27Z | |
| dc.date.available | 2026-01-24T12:29:27Z | |
| dc.date.issued | 2025 | |
| dc.department | Alanya Alaaddin Keykubat Üniversitesi | |
| dc.description.abstract | The intention of this work was to analyze that carvacrol could enhance cancer-inhibiting potency of cetuximab (monoclonal antibody) in lung cancer cells. The combination of cetuximab and carvacrol was found to co-operatively suppress cell proliferation by enhancing apoptosis and inducing cell cycle arrest in A-549 and H1299 cells. Furthermore, the combination therapy triggered cell death by inducing membrane disruption. The most effective combinations were IC10 cetuximab + IC10 carvacrol for A-549 and IC20 cetuximab + IC10 carvacrol for H1299 (CI = 2.0). LDH activity increased by 101% in A-549 and 239% in H1299 (p<0.05). Caspase-3 activity rose by 1.6-fold in A549 and 1.4-fold in H1299 (p<0.05). The combination decreased PCNA, topoisomerase II-alpha, and cyclins D1, D2, E, A, and B (p<0.05). Overall, the combination of carvacrol and cetuximab appears to enhance anti-cancer efficacy and may significantly improve therapeutic outcomes in lung cancer cells. | |
| dc.description.sponsorship | Scientific and Technological Research Council of Turkey (TUBITAK) [1919B012201653] | |
| dc.description.sponsorship | The author would like to thank the Scientific and Technological Research Council of Turkey (TUBITAK) (1919B012201653) for financial support of this work. | |
| dc.identifier.doi | 10.3329/bjp.v20i1.80949 | |
| dc.identifier.issn | 1991-007X | |
| dc.identifier.issn | 1991-0088 | |
| dc.identifier.issue | 1 | |
| dc.identifier.scopus | 2-s2.0-105005893503 | |
| dc.identifier.scopusquality | Q3 | |
| dc.identifier.uri | https://doi.org/10.3329/bjp.v20i1.80949 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12868/5372 | |
| dc.identifier.volume | 20 | |
| dc.identifier.wos | WOS:001480746800004 | |
| dc.identifier.wosquality | Q4 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.language.iso | en | |
| dc.publisher | Bangladesh Pharmacological Soc | |
| dc.relation.ispartof | Bangladesh Journal of Pharmacology | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.snmz | KA_WoS_20260121 | |
| dc.subject | Growth-Factor Receptor | |
| dc.subject | Monoclonal-Antibody | |
| dc.subject | Neck-Cancer | |
| dc.subject | Chemical-Composition | |
| dc.subject | Essential Oils | |
| dc.subject | Egfr | |
| dc.subject | Expression | |
| dc.subject | Antioxidant | |
| dc.subject | Chemotherapy | |
| dc.subject | Inhibition | |
| dc.title | Carvacrol enhances the sensitıvity of cetuximab in lung cancer cells through inducing apoptosis and cell cycle arrest | |
| dc.type | Article |












